Dongsung Pharmaceutical Requests Review of Improvement Plan Implementation - Corporate Review Committee to Convene by June 23, 2026

The company was granted an improvement period until May 13, 2026 after a corporate review committee decision on August 13, 2025.
On May 22, 2026, the company submitted an implementation report of its improvement plan requesting review.
KRX Securities Market Division will convene a corporate review committee within 20 business days from the submission date (by June 23, 2026).
The outcome may determine whether the company maintains its listing or faces delisting.

Filing: Other Market Guidance (Request for Review of Implementation of Improvement Plan)
Company: Dongsung Pharmaceutical (002210)
Submission: Securities Market Division
Receipt: 05-22-2026
Under KRX KOSPI Market Division